Transgene SA

Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025

22 май 2025 08:45:00 Источник Nasdaq GlobeNewswire

Transgene's Combined General Meeting of May 15, 2025

15 май 2025 08:45:00 Источник Nasdaq GlobeNewswire

Transgene Provides Business and Financial Update for Q1 2025

24 апр 2025 08:45:00 Источник Nasdaq GlobeNewswire

Availability of Preparatory Documents for the Combined General Meeting of May 15, 2025

23 апр 2025 23:00:00 Источник Nasdaq GlobeNewswire

Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025

23 апр 2025 08:45:00 Источник Nasdaq GlobeNewswire

Availability of Transgene’s 2024 Universal Registration Document (URD)

10 апр 2025 11:15:00 Источник Nasdaq GlobeNewswire

Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations

01 апр 2025 08:45:00 Источник Nasdaq GlobeNewswire

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ̶ Strong Outlook for 2025

27 мар 2025 09:45:00 Источник Nasdaq GlobeNewswire

Transgene to Participate in Upcoming Investor Meetings

11 мар 2025 09:45:00 Источник Nasdaq GlobeNewswire

Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts

06 фев 2025 08:45:00 Источник Nasdaq GlobeNewswire

Transgene to Participate in the Biomed Forum Investor Conference

21 янв 2025 08:45:00 Источник Nasdaq GlobeNewswire

Transgene Announces Financial Calendar for 2025

14 янв 2025 08:45:00 Источник Nasdaq GlobeNewswire

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2024

07 янв 2025 09:00:00 Источник Nasdaq GlobeNewswire

Transgene Reports Business, Pipeline and Financial Update for Q3 2024

07 ноя 2024 08:45:00 Источник Nasdaq GlobeNewswire

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

07 ноя 2024 08:45:00 Источник Nasdaq GlobeNewswire

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development

04 ноя 2024 22:30:00 Источник Nasdaq GlobeNewswire

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

13 окт 2024 22:30:00 Источник Nasdaq GlobeNewswire

Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024

06 окт 2024 23:00:00 Источник Nasdaq GlobeNewswire

2024 Half-Year Financial Report

24 сен 2024 08:45:00 Источник Nasdaq GlobeNewswire

Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025

24 сен 2024 08:45:00 Источник Nasdaq GlobeNewswire